Hangzhou Minsheng Institutes for Pharma Research;Hangzhou Minsheng Pharmaceuticals Co., Ltd.
发明人:
申请号：
EP12819928.8
公开号：
EP2740729A1
申请日:
2012.07.31
申请国别(地区):
EP
年份:
2014
代理人:
摘要：
A class of quinazoline derivatives or pharmaceutically acceptable salts or solvates thereof with novel structures is provided； meanwhile, a pharmaceutical composition comprising a pharmaceutically effective amountof said quinazoline derivatives or pharmaceutically acceptable salts or solvates thereof, and pharmaceutically acceptable excipients or additives is also provided. By modifying and transforming the quinazoline and screening of the transformed compounds on the activity of tyrosine kinase inhibition, most of the compounds have been found to possess inhibitory activity against one or several of EGFR, VEGFR-2, c-erbB-2, c-erbB-4, c-met, tie-2, PDGFR, c-src, lck, Zap70 and fyn kinases. The present invention has the advantages of reasonable design, broad source of and easy access to the raw materials, simple and easy operation of the preparation methods, mild reaction conditions, high yield of the products and being beneficial for industrial-scale production.
